Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Marne Carmichael Walsh

Physician Assistant Hilo, HI Physician Assistant

NPI 1609892900 CMS profile 10684203

670 Ponahawai St Ste 224, Hilo, HI 96720

Open in the dashboard

General payments

$16,684

480 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marne Carmichael Walsh of Hilo, HI is reported in the CMS Open Payments database as having received $16,684 across 480 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,607 131
2024 General $4,888 102
2023 General $3,778 119
2022 General $2,468 87
2021 General $943 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marne Carmichael Walsh
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Marne Carmichael Walsh were reported at $4,607. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Marne Carmichael Walsh Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $943 $132 $37–$438 $132
2022 $2,468 $155 $48–$522 $149
2023 $3,778 $167 $52–$557 $160
2024 $4,888 $178 $55–$600 $164
2025 $4,607 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,918 91 payments
  2. Sun Pharmaceutical Industries Inc. $2,082 60 payments
  3. Arcutis Biotherapeutics, Inc. $2,034 40 payments
  4. Regeneron Healthcare Solutions, Inc. $1,811 45 payments
  5. E.R. Squibb & Sons, L.L.C. $1,393 33 payments
  6. Lilly USA, LLC $1,146 45 payments
  7. LEO Pharma Inc. $808 30 payments
  8. Amgen Inc. $749 20 payments
  9. Galderma Laboratories, L.P. $724 25 payments
  10. Genzyme Corporation $675 15 payments
  11. Other $2,343 76 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,650 463 payments
  2. Education $1,034 16 payments
  3. Consulting Fee $1,000 1 payment
Products named General payments · program years 2021–2025
  1. Zoryve $1,756 30 payments
  2. RINVOQ $1,748 27 payments
  3. SOTYKTU $1,393 33 payments
  4. DUPIXENT Inflammation And Immunology $1,324 34 payments
  5. ILUMYA $1,271 51 payments
  6. TALTZ $1,057 42 payments
  7. DUPIXENT Immunology $894 16 payments
  8. Otezla $749 20 payments
  9. ADBRY $687 21 payments
  10. SKYRIZI $654 30 payments
  11. Other $6,959 257 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

203

Median for Physician Assistant: 241

Drug cost

$156,267

Median for Physician Assistant: $4,110

Branded share of claims

24.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 25 $102,455
Opzelura Ruxolitinib Phosphate Brand 14 $28,092
Enstilar Calcipotriene/Betamethasone Brand 11 $14,328
Clobetasol Propionate Generic 16 $2,971
Tacrolimus Generic 13 $2,629
Calcipotriene Generic 11 $1,620
Econazole Nitrate Generic 20 $879
Tretinoin Generic 11 $734
Imiquimod Generic 18 $649
Fluorouracil Generic 11 $622

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $1,309
$1,309 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $707
$707 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $625
$625 — —
DUPIXENT
  • GENZYME CORPORATION $218
  • Regeneron Healthcare Solutions, Inc. $189
$408 25 —
Bimzelx
  • UCB, Inc. $244
$244 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

480 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Hawaii

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record